Strides Pharma
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Strides Pharma's management has articulated a disciplined growth strategy, focusing on high-value therapeutic segments and operational efficiency despite geopolitical and inflationary pressures. The company's pivot towards complex generics, particularly in the Ex-US markets, is expected to bolster revenue growth, aligning with Vista's forecast of stable revenue performance. However, margins are anticipated to remain under pressure due to rising input costs and regulatory challenges in the US market. The favorable depreciation of the Indian Rupee is a significant tailwind, enhancing export revenues. Additionally, the company's strategic initiatives, including new product launches and cost optimization, support a cautiously optimistic outlook for H2FY27. While the overall sentiment remains stable, potential headwinds such as trade disruptions and energy cost volatility warrant close monitoring. Over the next 12-24 months, Strides Pharma is well-positioned to leverage its strengths in high-margin products and capitalize on favorable market dynamics, although vigilance regarding external pressures is essential
Why We Like This Stock
- Management's focus on high-value therapeutic segments is expected to drive long-term growth
- Favorable currency depreciation is likely to enhance export revenues
- New product launches and operational efficiencies are anticipated to support revenue stability
Things To Watch Out For
- Rising input costs and regulatory challenges in the US may pressure margins
- Geopolitical uncertainties could disrupt trade and impact performance
- Potential energy cost volatility poses risks to operational efficiency
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 3,890 | 4,565 | 4,859 | 5,060 | 5,590 |
| Profit Before Tax (Cr.) | 72 | 416 | 696 | 664 | 750 |
| PBT Margin | 1.9% | 9.1% | 14.3% | 13.1% | 13.4% |
| Net Profit (Cr.) | 119 | 3,559 | 614 | 587 | 644 |
| Earnings Per Share | 15.5 | 385.5 | 64.7 | 61.8 | 69.8 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasal sprays, topical formulations, and controlled substances; and therapeutic products, including antivirals, antibiotics, NSAIDs, and allergy treatment. It also provides branded generics, prescription medicines, and over-the-counter products for infectious diseases, pain management, cardiology, and wellness; and prescription generics for anti-infectives, CNS, cardiovascular, gastroenterology, pain management, and specialty products. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.